

REVIEW

Open Access



# Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US

Hyman M. Scott<sup>1\*</sup> and Jeffrey D. Klausner<sup>2</sup>

## Abstract

Pre-Exposure Prophylaxis (PrEP) has shown high efficacy in preventing human immunodeficiency virus (HIV) infection among men who have sex with men (MSM) in several large clinical trials, and more recently in “real world” reports of clinical implementation and a PrEP demonstration project. Those studies also demonstrated high bacterial sexually transmitted infection (STI) incidence and raised the discussion of how PrEP may impact STI control efforts, especially in the setting of increasing *Neisseria gonorrhoeae* antimicrobial resistance and the increase in syphilis cases among MSM. Here, we discuss STIs as a driver of HIV transmission risk among MSM, and the potential opportunities and challenges for STI control afforded by expanded PrEP implementation among high-risk MSM.

**Keywords:** STIs, HIV, PrEP, MSM

## Background

There have been exciting recent advances in human immunodeficiency virus (HIV) prevention for men who have sex with men (MSM) in the last several years, especially favorable results of three large clinical trials of Pre-Exposure Prophylaxis (PrEP) for HIV prevention [1–3]. The implementation of PrEP, and other HIV and sexually transmitted infection (STI) prevention strategies, is essential to reduce the estimated 30,000 new HIV diagnoses that occur among MSM in the US each year—with special attention to young MSM and MSM of color, groups disproportionately impacted by HIV infection [4, 5].

New strategies are also needed to address the rise in bacterial sexually transmitted infections (*Neisseria gonorrhoea*, *Chlamydia trachomatis*, and syphilis) as well among MSM in the US [6, 7]. Syphilis cases are of particular concern given the 47.9 % increase in diagnoses

between 2010 and 2014. With that increase in cases, several jurisdictions have also noted a rise in more severe syphilis complications, including a recent cluster of 18 ocular syphilis cases in San Francisco, California and Seattle, Washington—four of which resulted in at least partial visual loss, and two of which are legally blind after 5 months of follow-up [8].

The convergence of PrEP as a new HIV prevention strategy with an ongoing increase in STIs, has sparked important discussion about STI control challenges and opportunities in the setting of PrEP implementation among MSM [9].

## STIs as a driver of HIV incidence among MSM

Bacterial STIs have received significant attention as a potential driver of HIV infection among MSM since the beginning of the HIV epidemic [10, 11]. Several cohort studies of MSM initially identified a self-reported history of gonorrhea as an independent risk factor for HIV seroconversion, and both ulcerative and non-ulcerative STIs have been associated both epidemiologically and biologically with HIV infection [12–20]. Rectal STIs in particular have been identified as increasing the risk for HIV

\*Correspondence: hyman.scott@sfdph.org

<sup>1</sup> Bridge HIV, San Francisco Department of Public Health, San Francisco, CA, USA

Full list of author information is available at the end of the article

seroconversion, likely secondary to the higher per-contact transmission risk of HIV acquisition in condomless receptive anal intercourse due to the pro-inflammatory micro-environment, recruitment in HIV target cells, and mucosal immune cell activation [21]. A retrospective cohort of MSM demonstrated that two or more prior rectal gonococcal or chlamydial infections were associated with 8 times greater risk of HIV seroconversion [14]. Furthermore, a recent modeling analyses estimated the independent contribution of anorectal gonococcal or chlamydial infection on HIV incidence at approximately 15 % [22].

However, the challenge of quantifying the independent risk of bacterial STIs on HIV seroconversion risk has been confounded by sexual risk behavior. In an interesting analysis, Kelley et al., used propensity scores to control for confounding by behavioral risk and demonstrated a nearly threefold increased risk of HIV (Hazard ratio 2.7; 95 % Confidence interval (CI): 1.2–6.4) among MSM diagnosed with rectal gonorrhea or chlamydia in their cohort [23]. Syphilis was not associated with HIV acquisition, likely due to the low number of cases. A recent report from a cohort of MSM in San Diego diagnosed with recent or acute HIV infection between 2004 and 2014, did however identify syphilis as an independent predictor of HIV acquisition [24]. Other studies have also demonstrated a strong, independent association between recent syphilis infection and HIV acquisition [25].

While the increased risk of HIV acquisition with rectal STIs and syphilis has been demonstrated in controlled studies, it has been more difficult to demonstrate in “real world” settings. First, HIV and STI testing frequency is highly variable for MSM for a variety of patient and provider factors [26, 27]. Because the majority of STIs are asymptomatic in the absence of frequent screening the majority will be undiagnosed. In addition, the development of community norms regarding non-condom sexual risk reduction strategies can potentially decrease HIV risk, and concurrently increase STI risk [28]. For example, as early as 2006 in San Francisco, there was an increase in STI cases without a concurrent increase in HIV [29]. Seroadaptive sexual behaviors (e.g., serosorting or strategic positioning) were considered as a possible non-condom-related HIV risk reduction strategy employed by MSM to explain that discrepant observation [30, 31]. While seroadaptive behaviors have been associated with slightly reduced HIV risk (likely secondary to the associated difference lower per-contact risk of specific activities), they may increase risk for other STIs.

#### **PrEP clinical trials among MSM show high HIV risk reduction and STI incidence**

Several large clinical trials have studied the efficacy of PrEP for primary HIV prevention among MSM. The

Pre-Exposure Prophylaxis initiative (iPrEx) was the first large efficacy trial to show the efficacy of co-formulated tenofovir disoproxil fumarate/emtricitabine for primary HIV prevention among MSM [1]. Overall efficacy was 44 %, but was significantly higher among those with detectable drug levels indicating higher levels of adherence. Sexually transmitted infection incidence was also high in iPrEx, and a subsequent analysis showed a trend toward decreased reduction in protection among participants diagnosed with syphilis, although this was not statistically significant [25].

Results from other recent PrEP clinical trials have also demonstrated high STI incidence among study participants. The PROUD study demonstrated 86 % reduction in HIV risk among high-risk MSM offered PrEP as part of routine care at sexual health clinics in England [2]. Originally designed as a pilot study the HIV incidence among those in the delayed arm was 8.9/100 person-years. The study was able to target the highest risk men, as evidenced by both the high HIV incidence in the delayed study arm and that approximately 50 % of the cohort was diagnosed with at least one bacterial STI in follow-up. The Ipergay study also showed high PrEP efficacy, 86 % risk reduction when used for event-level instead of daily dosing, among high-risk MSM in Canada and France [32]. One third of study participants in the Ipergay study were diagnosed with an STI in follow-up, including six cases of hepatitis C (although it's not clear how many of those were sexually transmitted).

#### **STI incidence is also high among PrEP users in “real world” settings**

Given the high STI incidence observed in PrEP clinical trials, there has been concern about additional risk compensation—increased sexual risk behavior—in “real world” settings which has the potential to worsen the rising bacterial STI incidence. While there were no increases in sexual risk behavior overall in a recent PrEP demonstration project and report of PrEP implementation in a large healthcare system, some PrEP users did report an increase in risk behaviors, including a decrease in consistent condom use [28, 33]. In those recent reports approximately 50 % of participants were diagnosed with an STI within 12 months of follow-up. The high STI incidence in those studies, suggest that PrEP uptake occurred among the men at highest risk for HIV acquisition, but without a comparison group it is not possible to identify the role that PrEP may have played in modifying sexual risk behavior, if any, in the high STI incidence. Those studies also highlight the efficacy of PrEP in “real world” use as there were no HIV infections among the participants in the Kaiser San Francisco cohort (n = 657), and

only two HIV seroconversions among 557 participants in the PrEP Demonstration Project.

#### **Drug resistant gonorrhea is of public health importance**

*Neisseria gonorrhoeae* antimicrobial resistance is of urgent public health importance as *N. gonorrhoeae* have developed resistance to all currently available antibiotic regimens [34]. The current Centers for Disease Control and Prevention (CDC) recommendations for gonorrhea treatment include the use of dual therapy with two antimicrobials [35]. Resistance has developed to all classes of antibiotics and there is concern about further spread of multi-drug resistant clones among MSM, a core group for drug resistant gonorrhea transmission [36]. After a brief decline in 2013, the proportion of gonococcal isolates that had an elevated ceftriaxone minimal inhibitory concentration (MIC) ( $>0.125$   $\mu\text{g/ml}$ ) in the Gonococcal Isolate Surveillance Project increased in 2014 [37]. There have also been reported cases of isolates with even higher ceftriaxone MICs ( $>0.5$   $\mu\text{g/ml}$ ) and high-level azithromycin resistance [38, 39].

Increased STI screening and treatment will have important implications for STI control strategies to reduce the frequency of drug resistant gonococcal strains. Oropharyngeal gonococcal infections are an important source of ongoing gonorrhea transmission and also provide a microbiological environment conducive to the development of extended-spectrum cephalosporin resistance, through gene transfer with commensal *Neisseria* species that normally reside in the throat [40]. With improved screening frequency at extragenital sites like the oropharynx or rectum using more sensitive nucleic acid amplification tests and routine partner treatment, the earlier identification and treatment of gonococcal infections could enhance gonorrhea control [41, 42].

#### **Increased PrEP uptake is an opportunity to increase STI screening**

Although current CDC guidelines recommend routine and repeat screening for syphilis, and behaviorally based screening for gonorrhea and chlamydia, the rate of screening remains low [43, 44]. The vast majority of STIs are asymptomatic at pharyngeal and rectal sites, and studies suggest that more than 70 % would be missed with urogenital urine-based screening alone [17, 44, 45]. Many patients are not offered routine extragenital screening, even when seen at an STI clinic, and a recent study of HIV care providers showed that despite recommendations, routine STI screening was dismal [46]. Cited barriers included provider time constraints, difficulty obtaining a sexual history, language and cultural barriers, and concerns regarding patient confidentiality [46, 47].

PrEP is recommended as part of a comprehensive HIV prevention package which includes STI screening, risk reduction counseling, and condom promotion. As PrEP uptake increase, and is incorporated into various clinical settings, there is a substantial opportunity to improve STI screening frequency among high-risk MSM. Quarterly STI screening for men taking PrEP has the potential to increase the detection and treatment of STIs that would have otherwise been missed and potentially transmitted to sex partners. In an interesting observational cohort study of HIV-positive MSM, a clinic-based intervention of semiannual STI screening and risk reduction counseling reduced STI incidence in follow-up by 50 % between the 6 and 12 month visits, despite an increase in condomless anal sex with seroconcordant partners [48]. Increased STI screening coupled with enhanced partner services, including routine expedited partner therapy in MSM, may also provide an opportunity to engage sex partners for testing and treatment for further public health impact on both STI and HIV incidence.

While sexual risk compensation among PrEP users has been of concern, increased sexual risk behavior has not been observed in at least two of the PrEP clinical trials [2, 33]. PrEP uptake continues to expand among MSM and necessitates implementation of currently recommended and evaluation of new and innovative STI reduction strategies. One such strategy may be chemoprophylaxis for bacterial STIs, which could be incorporated into PrEP management. A recent pilot study by Bolan et al., demonstrated a significant reduction (Odds Ratio 0.27; 95 % CI: 0.09–0.83) in bacterial STIs among MSM randomized to receive once daily doxycycline compared to a behavioral intervention (contingency management) [49]. That STI prevention strategy is also being evaluated as a sub-study of Ipergay which has randomized study participants to event-driven prophylaxis with doxycycline (two doses of doxycycline after each sexual encounter—within at most 72 h post-event—up to a maximum of six tablets per week) vs. no doxycycline [50].

#### **Conclusions**

PrEP holds tremendous promise to reduce further HIV incidence among MSM, with appropriate targeting and implementation, and has along with treatment as prevention become the focus of combination HIV prevention. The implementation of PrEP as part of a comprehensive HIV prevention program, which includes frequent HIV testing, early HIV treatment and viral suppression, STI screening and condom promotion, also provides a tremendous opportunity to improve STI screening, treatment, and management with subsequent benefits in sexual and reproductive health. There was a steady rise in STIs among MSM before the widespread implementation

of PrEP, and the impact of the increased adoption of PrEP will be telling in the years to come. We have already witnessed a decoupling of STI and HIV incidence in some communities—increased STI incidence and lower HIV incidence—and it remains to be seen if, and how, PrEP will change these epidemiologic curves.

#### Authors' contributions

HMS and JDK prepared the original manuscript and contributed to subsequent revisions. Both authors read and approved the final manuscript.

#### Author details

<sup>1</sup> Bridge HIV, San Francisco Department of Public Health, San Francisco, CA, USA. <sup>2</sup> Division of Infectious Diseases: Global Health, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

#### Competing interests

The authors declare that they have no competing interests.

Received: 27 November 2015 Accepted: 3 January 2016

Published online: 19 January 2016

#### References

- Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010;363:2587–99.
- McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet*. 2015. doi:10.1016/S0140-6736(15)00056-2.
- Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. *N Engl J Med*. 2015;373:2237–46.
- Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. *AIDS Behav*. 2011;15(Suppl 1):S72–9.
- Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2013. HIV Surveillance Report, 2013;25. <http://www.cdc.gov/hiv/library/reports/surveillance/>. Published February 2015. Accessed 2 November 2015.
- Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2013. Atlanta: U.S. Department of Health and Human Services; 2014.
- Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2014. Atlanta: U.S. Department of Health and Human Services; 2015.
- Woolston S, Cohen SE, Fanfarin RN, Lewis SC, Marra CM, Golden MR. A cluster of ocular syphilis cases—Seattle, Washington, and San Francisco, California, 2014–2015. *MMWR Morb Mortal Wkly Rep*. 2015;64:1150–1.
- Koester KA, Grant RM. Editorial commentary: keeping our eyes on the prize: no new HIV infections with increased use of HIV Pre-exposure Prophylaxis. *Clin Infect Dis*. 2015;61:1604–5.
- Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. *Nat Rev Microbiol*. 2004;2:33–42.
- Berman SM, Cohen MS. STD treatment: how can it improve HIV prevention in the South? *Sex Transm Dis*. 2006;33:S50–7.
- Buchbinder SP, Douglas JM, McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. *J Infect Dis*. 1996;174:954–61.
- Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K, et al. Risk factors for HIV infection among men who have sex with men. *AIDS*. 2006;20:731–9.
- Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. *J Acquir Immune Defic Syndr*. 2010;53:537–43.
- Scott KC, Philip S, Ahrens K, Kent CK, Klausner JD. High prevalence of gonococcal and chlamydial infection in men who have sex with men with newly diagnosed HIV infection: an opportunity for same-day presumptive treatment. *J Acquir Immune Defic Syndr*. 2008;48:109–12.
- Koblin BA, Chesney MA, Husnik MJ, Bozeman S, Celum CL, Buchbinder S, et al. High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study. *Am J Public Health*. 2003;93:926–32.
- Kent CK, Chaw JK, Wong W, Liska S, Gibson S, Hubbard G, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: san Francisco, California, 2003. *Clin Infect Dis*. 2005;41:67–74.
- Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sex Transm Infect*. 1999;75:3–17.
- Zetola NM, Bernstein KT, Wong E, Louie B, Klausner JD. Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs. *J Acquir Immune Defic Syndr*. 2009;50:546–51.
- Buchbinder SP, Vittinghoff E, Heagerty PJ, Celum CL, Seage GR, Judson FN, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. *J Acquir Immune Defic Syndr*. 2005;39:82–9.
- Scott HM, Vittinghoff E, Irvin R, Sachdev D, Liu A, Gurwith M, et al. Age, race/ethnicity, and behavioral risk factors associated with per contact risk of HIV infection among men who have sex with men in the United States. *J Acquir Immune Defic Syndr*. 2014;65:115–21.
- Beck EC, Birkett M, Armbruster B, Mustanski B. A data-driven simulation of HIV spread among young men who have sex with men: role of age and race mixing and STIs. *J Acquir Immune Defic Syndr*. 2015;70:186–94.
- Kelley CF, Vaughan AS, Luisi N, Sanchez TH, Salazar LF, Frew PM, et al. The effect of high rates of bacterial sexually transmitted infections on HIV incidence in a cohort of black and white men who have sex with men in Atlanta, Georgia. *AIDS Res Hum Retroviruses*. 2015;31:587–92.
- Hoenigl M, Green N, Mehta SR, Little SJ. Risk factors for acute and early HIV infection among men who have sex with men (MSM) in San Diego, 2008 to 2014: a Cohort Study. *Medicine (Baltimore)*. 2015;94:e1242.
- Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, et al. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. *Clin Infect Dis*. 2014;59:1020–6.
- Helms DJ, Weinstock HS, Mahle KC, Bernstein KT, Furness BW, Kent CK, et al. HIV testing frequency among men who have sex with men attending sexually transmitted disease clinics: implications for HIV prevention and surveillance. *J Acquir Immune Defic Syndr*. 2009;50:320–6.
- Johnson CV, Mimiaga MJ, Reisner SL, Tetu AM, Cranston K, Berstrand T, et al. Health care access and sexually transmitted infection screening frequency among at-risk Massachusetts men who have sex with men. *Am J Public Health*. 2009;99(Suppl 1):S187–92.
- Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. *Clin Infect Dis*. 2015;61:1601–3.
- Truong HM, Truong HH, Kellogg T, Klausner JD, Katz MH, Dilley J, et al. Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? *Sex Transm Infect*. 2006;82:461–6.
- Hotton AL, Gratz B, Mehta SD. Association between serosorting and bacterial sexually transmitted infection among HIV-negative men who have sex with men at an urban lesbian, gay, bisexual, and transgender health center. *Sex Transm Dis*. 2012;39:959–64.
- Vallabhaneni S, Li X, Vittinghoff E, Donnell D, Pilcher CD, Buchbinder SP. Seroadaptive practices: association with HIV acquisition among HIV-negative men who have sex with men. *PLoS One*. 2012;7:e45718.
- Molina J-M, Capitant C, Charreau I, Meyer L, Spire B, Pialoux G, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on Retroviruses and Opportunistic Infections (CROI) 2015. Abstract 23LB. In.

33. Liu AY, Cohen SE, Vittinghoff E, et al. Pre-exposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. *JAMA Intern Med.* 2015;176(1):75–84.
34. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta: U.S. Department of Health and Human Services; 2013.
35. Workowski KA, Bolan GA. Prevention CfDca. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep.* 2015;64:1–137.
36. Lewis DA. The role of core groups in the emergence and dissemination of antimicrobial-resistant *N gonorrhoeae*. *Sex Transm Infect.* 2013;89(Suppl 4):iv47–51.
37. Kirkcaldy RD, Hook EW, Soge OO, del Rio C, Kubin G, Zenilman JM, et al. Trends in *Neisseria gonorrhoeae* susceptibility to cephalosporins in the United States, 2006–2014. *JAMA.* 2015;314:1869–71.
38. Gose SO, Soge OO, Beebe JL, Nguyen D, Stoltey JE, Bauer HM. Failure of azithromycin 2.0 g in the treatment of gonococcal urethritis caused by high-level resistance in California. *Sex Transm Dis.* 2015;42:279–80.
39. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2013: Gonococcal Isolate Surveillance Project (GISP) supplement and profiles. Atlanta: U.S. Department of Health and Human Services; 2015.
40. Lewis DA. Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant *Neisseria gonorrhoeae* strains? *Sex Transm Infect.* 2015;91:234–7.
41. Barbee LA, Dombrowski JC, Kerani R, Golden MR. Effect of nucleic acid amplification testing on detection of extragenital gonorrhoea and chlamydial infections in men who have sex with men sexually transmitted disease clinic patients. *Sex Transm Dis.* 2014;41:168–72.
42. Mayer KH, Klausner JD, Handsfield HH. Intersecting epidemics and educable moments: sexually transmitted disease risk assessment and screening in men who have sex with men. *Sex Transm Dis.* 2001;28:464–7.
43. Flagg EW, Weinstock HS, Frazier EL, Valverde EE, Heffelfinger JD, Skarbinski J. Bacterial sexually transmitted infections among HIV-infected patients in the United States: estimates from the medical monitoring project. *Sex Transm Dis.* 2015;42:171–9.
44. Patton ME, Kidd S, Llata E, Stenger M, Braxton J, Asbel L, et al. Extragenital gonorrhoea and chlamydia testing and infection among men who have sex with men—STD Surveillance Network, United States, 2010–2012. *Clin Infect Dis.* 2014;58:1564–70.
45. Gunn RA, O'Brien CJ, Lee MA, Gilchick RA. Gonorrhoea screening among men who have sex with men: value of multiple anatomic site testing, San Diego, California, 1997–2003. *Sex Transm Dis.* 2008;35:845–8.
46. Barbee LA, Dhanireddy S, Tat SA, Marrazzo JM. Barriers to bacterial sexually transmitted infection testing of HIV-infected men who have sex with men engaged in HIV primary care. *Sex Transm Dis.* 2015;42:590–4.
47. Carter JW, Hart-Cooper GD, Butler MO, Workowski KA, Hoover KW. Provider barriers prevent recommended sexually transmitted disease screening of HIV-infected men who have sex with men. *Sex Transm Dis.* 2014;41:137–42.
48. Patel P, Bush T, Mayer K, Milam J, Richardson J, Hammer J, et al. Routine brief risk-reduction counseling with biannual STD testing reduces STD incidence among HIV-infected men who have sex with men in care. *Sex Transm Dis.* 2012;39:470–4.
49. Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. *Sex Transm Dis.* 2015;42:98–103.
50. Ipergay: a study on the preventative therapy for STIs. July 10, 2015 <http://www.seronet.info/breve/ipergay-une-sous-etude-sur-traitement-preventif-pour-les-ist-72331>.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

